로그인|회원가입|고객센터|기업교육 문의
페이지 맨 위로 이동
검색

Clinical Trial

SCL Healthcare Expands Cancer Drug Analysis, Showcases Tech at ESMO

Dong-A Ilbo | Updated 2026.11.06
Provided by SCL Healthcare
SCL Healthcare is expanding its clinical trial sample analysis services required for the development of new anticancer drugs. After receiving additional designation for mass spectrometry items from the Ministry of Food and Drug Safety in April, the company recently attended the European Society for Medical Oncology (ESMO) to explore collaboration opportunities with global pharmaceutical and biotechnology companies.

SCL Healthcare announced that it participated as part of the Korean delegation organized by the Korea National Enterprise for Clinical Trials (KoNECT) at “ESMO 2026,” held in Madrid, Spain, from October 23 to 27. ESMO is an international academic event where cancer researchers, medical professionals, and pharmaceutical and biotechnology companies from around the world share the latest research outcomes in anticancer treatments.

At this event, the company showcased its sample analysis technologies using liquid chromatography–tandem mass spectrometry (LC-MS/MS), as well as its analysis services for antibody-drug conjugates (ADCs) and peptide drugs, precision flow cytometry analysis, and multiplex immunoassay platforms.

Antibody-drug conjugates are pharmaceuticals designed to deliver anticancer drugs to specific targets by conjugating them to antibodies. In clinical trials of such new drugs, sample analysis technologies are used to precisely measure in vivo drug concentrations and immune responses.

In response to an additional inquiry from Donga.com, SCL Healthcare explained that it provides pharmacokinetics (PK) and anti-drug antibody (ADA) assay development and validation services in the fields of ADCs and peptide drugs.

Pharmacokinetic analysis is the process of determining how a drug is absorbed, distributed, metabolized, and excreted in the body. Anti-drug antibody analysis is used to evaluate whether antibodies are formed as an immune response to the administered pharmaceutical.

The company plans to further advance its clinical trial sample analysis technologies for oligonucleotide therapeutics going forward. Oligonucleotide therapeutics are treatments that use short nucleic acid sequences to regulate the expression or function of specific genes.

Previously, at the American Society of Clinical Oncology (ASCO 2026) in May, SCL Healthcare also discussed potential collaboration with global companies, focusing on its pharmacokinetic analysis services.

Baek Se-yeon, Chief Operating Officer (COO) of SCL Healthcare and concurrently CEO of SCL Science, said, “Following ASCO 2026, at this ESMO event as well, there was strong interest from the global industry in SCL Healthcare’s unrivaled central laboratory (C-LAB) analysis capabilities,” adding, “The company will continue to strengthen its expertise in digital healthcare and precision analysis to become the most trusted new drug development partner for global pharmaceutical and biotechnology companies.”

SCL Healthcare’s central lab is a central testing laboratory specializing in clinical trial sample analysis, established in 2006. It was designated as a clinical trial sample analysis institution by the Ministry of Food and Drug Safety in 2019, and mass spectrometry items were added in April this year.

Choi Hyun-jeong

AI-translated with ChatGPT. Provided as is; original Korean text prevails.
Popular News

경영·경제 질문은 AI 비서에게,
무엇이든 물어보세요.

Click!